ANLN and hepatocellular carcinoma: The results showed that PDXs with high m6A ANLN methylation level displayed significant growth inhibition upon DZNeP treatment, while PDXs with low m6A ANLN methylation level expression did not respond to DZNeP, implying that employing DZNeP to inhibit the m6A-ANLN axis may be a promising therapeutic option for HCC BM patients.